YARAL Pharma Now the Exclusive Supplier of Authorized Generic Levothyroxine Sodium Capsules in the U.S. Market

Press Release
Article

YARAL Pharma Inc. (YARAL Pharma), the U.S. generics subsidiary of IBSA (Institut Biochimique SA), a multinational pharmaceutical company headquartered in Lugano, Switzerland, today announced that they are now the exclusive supplier of the authorized generic levothyroxine sodium capsules in the United States. Levothyroxine Sodium Capsules are used to treat hypothyroidism.

“When it comes to managing hypothyroidism, not all levothyroxine medications are created equal,” said Stephen Beckman, CEO of YARAL Pharma. “Each year, millions of patients are treated with levothyroxine. For those who have trouble tolerating traditional levothyroxine tablets, the answer may lie in the dosage form. YARAL is pleased to offer patients a high-quality gel capsule product, specially formulated to improve the tolerability of LT4 therapy, supported by continuity of supply, and an exceptional level of customer service.”

YARAL Pharma’s Levothyroxine Sodium Capsules, a unique gel-cap formulation designed to address concerns of absorption and tolerability commonly found in levothyroxine tablets are available in twelve dosage strengths. The capsules contain only four simple ingredients: levothyroxine, gelatin, glycerin and water, and are free from sugars, dyes, alcohol, wheat starch (gluten), and lactose.1 This is especially important for patients with hypothyroidism who have allergies or sensitivities to ingredients commonly found in levothyroxine tablets or for those with certain gastrointestinal conditions.2

INDICATIONS AND USAGE
Hypothyroidism primary (thyroidal). Secondary Levothyroxine Sodium Capsules is indicated as a replacement therapy in adults and pediatric patients 6 years and older with (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression Levothyroxine Sodium Capsules is indicated as an adjunct to surgery and radioiodine therapy in the management of adults and pediatric patients 6 years and older with thyrotropin-dependent well-differentiated thyroid cancer.

References

  1. Levothyroxine Sodium Capsules [package insert]. Parsippany, NJ: YARAL Pharma Inc; 2021.
  2. McMillan M, Rotenberg KS, Vora K, et al. Comorbidities, concomitant medications, and diet as factors affecting levothyroxine therapy; results of the CONTROL Surveillance Project. Drugs in R&D. 2015;16(1):53-68.
Recent Videos